March 17, 2025 03:56 PM EDT
Pharma
Law

Trump’s HHS de­fends Biden-era stance on 340B re­bate mod­els

Nicole DeFeudis

Editor

The Trump ad­min­is­tra­tion de­fend­ed HHS’ re­jec­tion of drug­mak­ers’ 340B re­bate mod­els “at this time,” but sug­gest­ed that the agency could be open to fur­ther con­sid­er­a­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

FDA staff re­turn to White Oak cam­pus en masse af­ter Trump ad­min­is­tra­tion push

In­cyte's stock sinks as piv­otal skin dis­ease da­ta dis­ap­point

As­traZeneca taps Al­teogen in deal worth more than $1.3B to make sub­cu­ta­neous can­cer drugs

Post-Hoc: Kennedy's an­ti-vac­cine ac­tions should­n't sur­prise any­one

Avid­i­ty seeks to 'set the stan­dard' as it heads to FDA with Duchenne drug

As­traZeneca re­ports Phase 3 suc­cess for rare dis­ease drug at heart of Amolyt deal

A service from the Financial Times